Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026
EXPRESS: High-resolution three-dimensional characterization of clot evolution in experimental intracerebral hemorrhage using diceCT.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Tianjie, Xia Fan, Teng Bang, Fang Mei, Wang Jiayan, Wang Zexu, Wen Dingke, Tao Chuanyuan, Ma Lu, Hu Xin
Аннотация
BACKGROUND: MRI is widely used to monitor experimental intracerebral hemorrhage (ICH), but T2*-weighted lesion volume may reflect both clot components and blood degradation products during hematoma evolution. We utilized diffusible iodine-based contrast-enhanced CT (diceCT) to examine diceCT-visible clot changes in relation to MRI-defined lesions.
METHODS: ICH was induced in 102 mice via collagenase or autologous blood infusion. DiceCT was performed at 4 hours, 1, 3, 7 and 28 days post-ICH. In paired MRI-diceCT cohorts, diceCT-visible clots were compared with T2*-weighted MRI lesions.
RESULTS: DiceCT enabled volumetric assessment of clot components and erythrolysis-associated intralesional hypodense regions after ICH. High-resolution imaging revealed vascular-associated clot extensions toward the brain surface. Multimodal analysis revealed an early shift in hemorrhagic lesion composition: the fraction of the MRI-defined T2* lesion represented by diceCT-visible clot decreased markedly by day 7 (16.92% in the autologous blood model and 2.59% in the collagenase model).
CONCLUSION: DiceCT provides high-resolution ex vivo visualization of clot structures after experimental ICH. Combined MRI-diceCT analysis indicates that MRI-defined lesions and diceCT-visible clot structures diverge over time, supporting the use of complementary imaging readouts to characterize hematoma evolution and persistent blood-derived signals after ICH.
METHODS: ICH was induced in 102 mice via collagenase or autologous blood infusion. DiceCT was performed at 4 hours, 1, 3, 7 and 28 days post-ICH. In paired MRI-diceCT cohorts, diceCT-visible clots were compared with T2*-weighted MRI lesions.
RESULTS: DiceCT enabled volumetric assessment of clot components and erythrolysis-associated intralesional hypodense regions after ICH. High-resolution imaging revealed vascular-associated clot extensions toward the brain surface. Multimodal analysis revealed an early shift in hemorrhagic lesion composition: the fraction of the MRI-defined T2* lesion represented by diceCT-visible clot decreased markedly by day 7 (16.92% in the autologous blood model and 2.59% in the collagenase model).
CONCLUSION: DiceCT provides high-resolution ex vivo visualization of clot structures after experimental ICH. Combined MRI-diceCT analysis indicates that MRI-defined lesions and diceCT-visible clot structures diverge over time, supporting the use of complementary imaging readouts to characterize hematoma evolution and persistent blood-derived signals after ICH.